Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
Submitted by
admin
on January 27, 2022 - 11:36pm
Source:
Motley Fool
News Tags:
Amgen
Europe
Lumykras
non-small cell lung cancer
Headline:
Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug
snippet:
Amgen has gained access to around 10,000 patients in the European Union.
This should generate $300 million in annual sales for the company.
Amgen looks like a great dividend growth stock to buy at this time.
Do Not Allow Advertisers to Use My Personal information
